- Home
- ITOS
as 06-20-2025 3:37pm EST
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 270.7M | IPO Year: | 2020 |
| Target Price: | $10.60 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Hold | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.80 - $18.13 | Next Earning Date: | 08-07-2025 |
| Revenue: | $35,000,000 | Revenue Growth: | 177.89% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of iTeos Therapeutics Inc. (ITOS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Detheux Michel | ITOS | Chief Executive Officer | Jun 9 '25 | Sell | $10.03 | 104,565 | $1,048,264.12 | 135,903 | |
| Detheux Michel | ITOS | Chief Executive Officer | Jun 4 '25 | Sell | $10.15 | 156,847 | $1,592,519.82 | 135,903 | |
| Hallal David | ITOS | Director | Jun 4 '25 | Sell | $10.15 | 114,682 | $1,164,404.66 | 0 | |
| EcoR1 Capital, LLC | ITOS | 10% Owner | May 14 '25 | Buy | $7.70 | 4,958,978 | $38,685,561.58 | 7,388,978 | |
| MPM BIOVENTURES 2018, L.P. | ITOS | N/A | May 13 '25 | Sell | $8.06 | 630,191 | $5,079,339.46 | 2,108,594 | |
| MPM BioVentures 2014, L.P. | ITOS | N/A | May 13 '25 | Sell | $8.06 | 630,191 | $5,079,339.46 | 2,108,594 | |
| GADICKE ANSBERT | ITOS | N/A | May 13 '25 | Sell | $8.06 | 1,031,931 | $8,317,363.86 | 3,452,797 |
Latest iTeos Therapeutics Inc. News
ITOS Breaking Stock News: Dive into ITOS Ticker-Specific Updates for Smart Investing
MT Newswires
9 days ago
ITeos Therapeutics Insider Sold Shares Worth $1,048,264, According to a Recent SEC Filing
MT Newswires
12 days ago
iTeos Therapeutics Insider Sold Shares Worth $1,592,520, According to a Recent SEC Filing
MT Newswires
12 days ago
iTeos Therapeutics Insider Sold Shares Worth $1,164,405, According to a Recent SEC Filing
Zacks
22 days ago
iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know
Pharmaceutical Technology
23 days ago
iTeos to shut down following $2bn GSK-partnered TIGIT asset failure
MT Newswires
24 days ago
Wedbush Downgrades iTeos Therapeutics to Neutral From Outperform, Adjusts Price Target to $12 From $10
MT Newswires
24 days ago
iTeos Therapeutics to Wind Down Operations
GlobeNewswire
24 days ago
iTeos Therapeutics Announces Its Intention to Wind Down Operations
Compare ITOS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ITOS iTeos Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.